This preclinical study develops a murine model to examine osteonecrosis in mice, suggesting timing for interventions.
This study establishes a murine model of corticosteroid-associated osteonecrosis of the femoral head (ONFH) using a sustained-release prednisolone pellet and evaluates mitochondrial stress using 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) and changes in key histologic markers of bone over a 6-week period. Sixteen 12-week-old Balb/C mice were divided into two groups: a prednisolone group (PRED) and a control group (SHAM). The PRED group received a subcutaneous 60-day sustained-release pellet containing 2.5 mg of prednisolone, while the SHAM group received placebo pellets. PET/CT imaging was performed at 1, 3, and 6 weeks. Bone mineral density (BMD) measurements, and histomorphological analyses for the number of empty lacunae, osteoblasts, osteoclasts, and NADPH oxidase (NOX) 2, a marker for oxidative stress, were conducted at 4 or 6 weeks. PET/CT imaging demonstrated increased uptake in the femoral head at 3 weeks in the PRED group. This was accompanied by increased numbers of empty lacunae and osteoclasts, increased oxidative stress, and decreased alkaline phosphatase staining at 4 weeks in the PRED group. We have successfully established and validated a small murine model of ONFH. The findings of this preclinical study suggest a critical timeline for potential interventions to mitigate the early adverse effects of continuous corticosteroid exposure on bone.
No takes yet. Share an insight, caveat, or question.
Shinohara et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: